Breast Cancer ‘Immunotherapy’ Helps Some – WebMD
|
Breast Cancer ‘Immunotherapy‘ Helps Some
WebMD MONDAY, April 3, 2017 (HealthDay News) — Women with a particularly aggressive form of breast cancer who responded to an new immune-focused drug gained a significant survival benefit, a new study shows. The patients all had what’s known as advanced … |
Fred Hutch News Service |
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer
Fred Hutch News Service Dr. Paul Nghiem of the University of Washington and Fred Hutch was a senior investigator on a trial of an immunotherapy drug in chemotherapy-resistant, metastatic Merkel cell carcinoma, a rare skin cancer. The one-year follow-up data were presented at … |
Daily Mail |
Scans reveal colours of cancer cells and body’s defence
Daily Mail Dr Emma Smith, Cancer Research UK’s science information manager, said: ‘These stunning images show white blood cells, called CAR T cells, in action after they have been retrained to spot and attack cancer cells. ‘Immunotherapy is an important new … |
|
Nanoparticle treatment could improve immunotherapy against cancer UNC Lineberger Comprehensive Cancer Center
EurekAlert (press release) “Our data shows that two compounds on a single nanoparticle will make immunotherapy treatments even more effective,” said the study’s senior author Andrew Wang, MD, a UNC Lineberger member and associate professor in the UNC School of Medicine … |
Sports Perspectives |
Bristol-Myers immunotherapy combination extends survival in melanoma
WHTC (Reuters) – Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years … BMS to Use Foundation Medicine Platform in Immuno-Oncology PartnershipGenetic Engineering & Biotechnology News (blog) |
The Cerbat Gem |
Bristol-Myers immunotherapy combination extends survival in melanoma
Reuters Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years, according … Bristol-Myers Squibb Enters Collaboration To Leverage Foundation Medicine’s Molecular Information PlatformBio-IT World BMS to Use Foundation Medicine Platform in Immuno-Oncology PartnershipGenetic Engineering & Biotechnology News (blog) Five things for pharma marketers to know: Monday, April 3, 2017Medical Marketing and Media GenomeWeb –Endpoints News –MilTech all 102 news articles » |
|
Bristol-Myers immunotherapy combination extends survival in melanoma
Reuters Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years, according … |